1HE J,GU DF,WU XG,et al.Major cause of death among men and women in china.N Engl J Med,2005,353:1124-1134
2杨宝峰主编.药理学.第6版.北京:人民卫生出版社,2005.267.
3Guidelines Committee.2003 European Societ of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension.J Hypertens,2003,21:1021-1053
4Chobanian A,Bakris GL,Black HR,et al.The seventh report of the Joint National Committee on prevention,detection,evaluation and treatment of high blood pressure:The JNC7 report.JAMA,2003,289(19):2560-2572
5Malacco E,Vari N,Capuano V,et al.A randomized,double-blind,active-controlled,parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients:the Val-Syst study.Clin Ther,2003,25(11):2765-2780
6Liu L,Zhang Y,Liu GZ,et al.For FEVER Study Group.The Felodipine Event Reduction (FEVER) study:A randomized long-term placebo controlled trial in Chinese hypertensive patients.J Hypertens,2005,23:2157-2172
7Julius S,Kjeldsen ES,Weber M,et al.The VALUE trial group outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomized trial.Lancet,2004,363(9426):2022-2031
8The ALLHAT Officers and Coordinators for the ALLHAT Collaboratire research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzume inhibitor or calcium channel blocker vs diuretic:the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).JAMA,2002,288:2981-2997
9Blood Pressure Lowering Treatment Trialists Collaboration.Effects of different blood-pressure-lowering regiments on major cardiovascular events:results of prospectively-designed ovrviews of randomized trials.Lancet,2003,362:1527-1545
10Mancia G,Ruilope L,Palmer C,et al.Effects of nifedipine GITS and diuretic in isolated systolic hypertension-a subanalysis of INSIGHT Study.Blood Press,2004,13:310-315
二级参考文献25
1Song YM, Sung J, Lawlor DA, Smith DG, Shin Y, Ebrahim S.Blood pressure, haemorrhagic stroke, and ischaemic stroke : the Korean national prospective occupational cohort study [J]. BMJ, 2004 ;328(7435): 324-325.
2He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials[J ]. Am Heart J, 1999; 138(3 Pt2): 211 -219.
3Luscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension, A reappraisal[J].Drugs, 1998; 55(4): 509-517.
4Asmar R, Benetos A, Ghodsi N, Meilhac B, Safar M. Regional arterial hemodynamics and carotid circulation in essential arterial hypertension. Effect of nitrendipine in patients over 40 years of age[J].Presse Medicale, 1993 ; 22(35) : 1770 - 1775.
5Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. European Lacidipine Study on Atherosclerosis investigators.Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind,long-term trial[J ]. Circulation, 2002 ; 106 ( 19 ) : 2422 - 2427.
6Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes[J ]. Circulation, 2001 ; 103 (24) : 2949 - 2954.
7Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews ofrandomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration [ J ]. Lancet, 2000; 356(9246) : 1955 - 1964.
8Kaplan NM. Hypertension trials: 1990 to 2000[J]. Current Opinion in Nephrology & Hypertension, 2001 ; 10 ( 4 ) : 501 - 505.
9Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy[Jl. Journal of the American College of Cardiology, 2002; 39(2): 315-322.
10Kloner RA, Vetrovec GW, Materson BJ, Levenstein M. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients[J]. American Journal of Cardiology, 1998; 81 (2): 163-169.
